Market Cap
$4.9B
DNTH
Dianthus Therapeutics, Inc. /DE/
$90.13 ▲ +2.05%
Prev close $88.32Market cap$4.9B
ConsensusStrong Buy
12-mo target$140.80 (+56.2%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)37 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on DNTH right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$3.7B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $31.7M sell
Insider Net $
-$31.7M
SEC Reports
11
Press Releases
5
Price chart 30d -15.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:
Sep 17, 2026 Insider
CARR EDWARD sold 700 shares
CHIEF ACCOUNTING OFFICER @ $104.39 ($73.1K)
Sep 17, 2026 Insider
CARR EDWARD acquired via exercise 20,000 shares
CHIEF ACCOUNTING OFFICER @ $17.88 ($357.6K)
Sep 17, 2026 Insider
Aug 15, 2026 SEC CARR EDWARD sold 7,928 shares
CHIEF ACCOUNTING OFFICER @ $100.43 ($796.2K)
Multiple Dianthus Therapeutics insiders, including CEO Marino and GC Veness, executed open-market sales totaling $3.15M
CLUSTER — Impact 4/10
A cluster of insider selling at Dianthus Therapeutics (DNTH) totaling $2.99M over a 7-day window, led by the CEO ($1.12M
CLUSTER — Impact 3/10
Three Dianthus Therapeutics insiders (CEO, General Counsel, and a Director) sold a total of ~$3.2M in open-market shares
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
4,123,822 shares ($402.0M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 11, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| Sep 4, 2026 | Citigroup | INITIATE | Buy | 55% |
| Aug 6, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 5, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Aug 3, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| May 6, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Apr 9, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 11 | 11 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% |
Price targets
Where 15 covering analysts think DNTH trades over the next 12 months.
$140.80 +56.2% upside Strong Buy
Current$90.13 Low$122.00 Median$134.00 High$200.00 15 analysts
$122.00$200.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 3 bullish, 3 bearish, 0 mixed, 5 neutral · avg impact 4.9/10.Plus 5 press releases.
NEUTRALCLUSTER4/10
Multiple Dianthus Therapeutics insiders, including CEO Marino and GC Veness, executed open-market sa
Aug 15, 2026
NEUTRALCLUSTER3/10
A cluster of insider selling at Dianthus Therapeutics (DNTH) totaling $2.99M over a 7-day window, le
Aug 12, 2026
NEUTRALCLUSTER3/10
Three Dianthus Therapeutics insiders (CEO, General Counsel, and a Director) sold a total of ~$3.2M i
Aug 11, 2026
BEARISHCLUSTER6/10
CEO Marino Garcia and General Counsel Adam Veness executed a cluster of open-market sales totaling ~
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedi
Sep 14, 2026
Clinical Trial
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 14, 2026
clinical_trial_readout
T-90d Trial Readout: Claseprubart (Phase 2)
Trial: A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Sponsor: Dianthus Therapeutics Phase: Phase 2 | Status: ACTIVE_
Sep 8, 2026
clinical_trial_readout
T-90d Trial Readout: Claseprubart (Phase 2)
Trial: A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Sponsor: Dianthus Therapeutics Phase: Phase 2 | Status: ACTIVE_
Sep 2, 2026
other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company ded
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.95 | $-1.13–$-0.39 | 2.2% | +7.0% | 2↑ 1↓ | $0.0B | 10 |
| Next Q | $-1.11 | $-1.36–$-0.98 | 22.3% | +2.5% | 2↑ 1↓ | $0.0B | 10 |
| Current FY | $-3.81 | $-4.10–$-3.43 | 9.2% | +2.7% | 2↑ 1↓ | $0.0B | 11 |
| Next FY | $-4.61 | $-5.77–$-3.47 | -20.9% | +2.8% | 2↑ 1↓ | $0.0B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.949 | — |
| 7d ago | $-0.949 | — |
| 30d ago | $-1.020 | +0.071 |
| 60d ago | $-1.022 | +0.074 |
| 90d ago | $-1.022 | +0.074 |
Institutional ownership
Which big funds own DNTH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.7B total value (38,087,876 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 8,199,893 | $799.3M | 21.6% | — |
| BlackRock, Inc. | 4,123,822 | $402.0M | 10.9% | ADD +29.9% |
| WELLINGTON MANAGEMENT GROUP LLP | 3,229,882 | $314.8M | 8.5% | — |
| STATE STREET CORP | 2,357,440 | $229.8M | 6.2% | ADD +68.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,159,568 | $210.5M | 5.7% | — |
| FRED ALGER MANAGEMENT, LLC | 1,302,493 | $127.0M | 3.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,258,502 | $122.7M | 3.3% | ADD +37.4% |
| UBS Group AG | 1,140,260 | $111.2M | 3.0% | ADD +45.9% |
| JENNISON ASSOCIATES LLC | 1,021,763 | $99.6M | 2.7% | DOUBLED +110.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 3,175,703 | 4,123,822 | +29.9% | $402.0M |
| STATE STREET CORP | ADD | 1,398,913 | 2,357,440 | +68.5% | $229.8M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 916,211 | 1,258,502 | +37.4% | $122.7M |
| UBS Group AG | ADD | 781,282 | 1,140,260 | +45.9% | $111.2M |
| JENNISON ASSOCIATES LLC | DOUBLED | 485,136 | 1,021,763 | +110.6% | $99.6M |
| CITADEL ADVISORS LLC | TRIM | 1,610,483 | 974,911 | -39.5% | $95.0M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 349,381 | 570,115 | +63.2% | $55.6M |
| AMERIPRISE FINANCIAL INC | ADD | 358,470 | 531,999 | +48.4% | $51.9M |
| NORTHERN TRUST CORP | ADD | 303,752 | 411,791 | +35.6% | $40.1M |
| GOLDMAN SACHS GROUP INC | TRIM | 548,010 | 382,161 | -30.3% | $37.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$31.7M — $0.00 bought, $31.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 700 | $104.39 | $73.1K |
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | EXERCISE | 20,000 | $17.88 | $357.6K |
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 7,928 | $100.43 | $796.2K |
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 6,771 | $101.37 | $686.4K |
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 3,501 | $102.39 | $358.5K |
| Sep 17, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 1,100 | $103.20 | $113.5K |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | EXERCISE | 9,375 | $22.07 | $206.9K |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | SELL | 2,600 | $105.19 | $273.5K |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | SELL | 7,215 | $106.25 | $766.6K |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | EXERCISE | 6,249 | $21.77 | $136.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DNTH.
Shares short
8,829,663
Settlement Sep 15, 2026
Change vs prior
+4.7%
Semi-monthly cycle
Days to cover
14.4
At avg daily volume
Of shares outstanding
≈15.8%
Estimate — not % of float
All DNTH filing & press-release reports (16)
- CLUSTER reportAug 15, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 11, 2026
- 144 reportAug 11, 2026
- PRESS-RELEASE reportJun 29, 2026
- 8-K reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMar 17, 2026
- CLUSTER reportMar 14, 2026
- PRESS-RELEASE reportMar 12, 2026
- 8-K reportMar 12, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 9, 2026
- PRESS-RELEASE reportMar 8, 2026